|
|
|
| home > ebr > spring 2003 > the importance of provisional protection for biotech inventions |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| With the biotech industry developing into a pipeline feeder for the pharmaceutical industry to a certain extent, biotech companies are having to seek new ways of protecting some of their most valuable assets. Provisional protection available under the most important legal systems such as the European Patent Convention, US Patent Act and Japanese Patent Act offer an opportunity which to date has been mostly unexplored. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Dr Armin Bohmann, Founder and Partner of Bohmann & Loosen, and Dr Ulrich Gerth, Vice President of Equity Corporate Finance at Hypovereinsbank Corporates & Markets
Dr Armin K Bohmann is Founder and Partner of Bohmann & Loosen, which was established in August 2000. Armin was previously Head of the Biotech Department of a leading German law firm specialising in intellectual property. His interests are IP matters related to biotechnology, chemistry and pharmacy; including prosecution, litigation and licensing.
Armin received a Diploma in Molecular Biology from the Technical University of Munich and a Doctorate Degree in Bioprocess and Biochemical Engineering, and spent one year as a postdoctoral in Japan.
Dr Ulrich C Gerth is Vice President of Equity Corporate Finance at HVB Corporates & Markets. He joined the company in April 2000, working in the biotech and life sciences sector on technology, products and business models. He moved to the corporate finance department in July 2001.
Ulrich previously worked as a Consultant for Ernst & Young's life sciences team. He was responsible for pre-IPO evaluations, consultation and market research, and was a co-author of two of their European Life Sciences Reports. After gaining a degree in Biochemistry from the University of Witten/Herdecke, Ulrich obtained his doctorate degree in Molecular Medicine at Oxford University, UK.
|
|
|
|
|
|
 |
Industry Events |
 |
3rd African Regulatory Conference (ARC)
3-4 May 2012, Accra, Ghana
The African Regulatory Conference offers the opportunity for key stakeholders active on the continent, including representatives from Ministry of Health, local and multinational pharmaceutical companies, to meet to exchange views, discuss topics of interest and identify focus areas for ongoing efforts to increase patient access to new and improved medicines.
More info >> |
|
 |
News and Press Releases |
 |
Record sales of new de-blistering and leak testing equipment at packaging machinery manufacturer, Sepha Ltd
The packaging machinery manufacturer, Sepha Ltd, has reported record sales of its recently extended range of non-destructive leak testing equipment for the world's pharmaceutical packaging industry. With demand up across all major markets, the company says the increase will fund future R&D and enable it to bring forward future innovations aimed at reducing costs and driving quality for pharmaceutical manufacturers and contract packers.
More info >> |
|
|
